Cogent Biosciences Q3 net loss $55.4M; cash $312.8M providing runway into 2026

Cogent Biosciences, Inc.

2023-Q3 EPS reported -$1.79

Net loss of $55.4M for Q3 2023 vs $35.1M in Q3 2022; R&D expenses $50.1M (up 67% YoY).
Cash, cash equivalents and marketable securities $312.8M as of Sept 30, 2023, down from $350.9M at June 30, 2023.
SUMMIT NonAdvSM trial Part 1 enrollment completed at 54 patients; Part 2 registration-directed trial to begin 1H 2024.
APEX AdvSM trial Part 2 enrollment on track to complete by end 2024; SUMMIT Part 1a data selected for oral presentation at ASH 2023.
PEAK Phase 3 GIST study lead-in data shows 33% ORR in 2nd-line; Phase 3 enrollment on track by end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cogent Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-057785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.